Hotchkis & Wiley Capital Management LLC Acquires Shares of 222,620 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Hotchkis & Wiley Capital Management LLC bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 222,620 shares of the company's stock, valued at approximately $10,804,000. Hotchkis & Wiley Capital Management LLC owned 0.46% of Amphastar Pharmaceuticals as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after buying an additional 273 shares during the period. Innealta Capital LLC purchased a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $55,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 53.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock valued at $56,000 after purchasing an additional 398 shares in the last quarter. Blue Trust Inc. lifted its position in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock worth $70,000 after purchasing an additional 309 shares during the last quarter. Finally, Asset Management One Co. Ltd. acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter worth $78,000. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH traded down $0.70 during mid-day trading on Thursday, reaching $43.60. 699,727 shares of the stock were exchanged, compared to its average volume of 399,762. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The company has a 50 day simple moving average of $47.68 and a 200-day simple moving average of $44.59. The stock has a market capitalization of $2.10 billion, a P/E ratio of 14.77, a P/E/G ratio of 0.89 and a beta of 0.78.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on AMPH shares. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 price target for the company. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating for the company in a report on Thursday, August 8th. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Finally, Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $60.33.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of the company's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the transaction, the director now owns 31,471 shares in the company, valued at approximately $1,535,784.80. This represents a 13.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares in the company, valued at approximately $3,900,522.90. The trade was a 6.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,533 shares of company stock worth $1,238,842 in the last 90 days. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.